louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03366311: TCHCCT-Zhong-Xing-Emergency-Department-airway
Official title: TCH-Zhong-Xing-Branch-Emergency-Department
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Airway Complication of Anesthesia
Intubation;Difficult
Keywords: intubation
epiglottis lift
hold high position
Lead sponsor: Taipei City Hospital
Sponsor class: OTHER_GOV
First posted: 2017-12-08
Enrollment: 45
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Prospective randomised crossover manikin study
Primary purpose: TREATMENT

Brief summary: To investigate which shapes of stylet, hand techniques and possible condition that improve intubation successful rate and reduce the elapsed intubation time.

Detailed description: Challenging airway is always a big issue in emergency room. However, better hand technique, stylet shapes and conditions affecting intubation successful rate, elapsed duration need further investigations. We compare two endotracheal tube holding position, two holding places, with or without epiglottis lift technique in this study. All intubation processes in the study will be recorded.

Eligibility criteria: Inclusion Criteria:

* care givers with sufficient understanding of airway anatomy and management

Exclusion Criteria:

* N/A

Primary outcomes:
measure: intubation successful rate
timeFrame: through study completion, and average of 15minutes
Secondary outcomes:
measure: intubation elapsed time
timeFrame: through study completion, and average of 15minutes
measure: insertion elapsed time
timeFrame: through study completion, and average of 15minutes
measure: difficulty of intubation
timeFrame: through study completion, and average of 15minutes
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Taipei City Hospital Zhong-Xing branch
Study officials:
affiliation: Taipei City Hospital ZhongXing Branch
name: Tzu-Yao Hung, MD
role: STUDY_DIRECTOR
References:
citation: Hung TY, Lin LW, Yeh YH, Su YC, Lin CH, Yang TF. The evaluation of a better intubation strategy when only the epiglottis is visible: a randomized, cross-over mannequin study. BMC Anesthesiol. 2019 Jan 10;19(1):8. doi: 10.1186/s12871-018-0663-9.
Clinical trial NCT04668911: Oral Health, Microbial Burden and COVID-19
Official title: Oral Health, Microbial Burden and COVID-19
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Covid19
Periodontitis
Keywords: COVID-19
Human microbiome
Oral microbiome
SARS-CoV-2 infection
Lead sponsor: Eastman Dental Insitute and Hospital
Sponsor class: OTHER
Collaborators: name: DermBiont, Inc.
name: University College London Hospitals
name: The Whittington Hospital NHS Trust
First posted: 2020-12-16
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults who tested (PCR) positive or negative for SARS-CoV2 infection

Brief summary: An observational study of patients with COVID-19 confirmed cases (with various degrees of severity) and controls.

Oral and nasal swabs will be taken from 150 patients (50 with mild form and 50 with severe form of COVID-19 with or without mechanical ventilation, 50 healthy controls).


Eligibility criteria: Inclusion Criteria:

1. Must provide written informed consent
2. Subjects have to be tested (PCR) positive or negative for SARS-CoV2 infection
3. Must be able to provide oral and nasal swabbing within 48 hours of polymerise chain reaction (PCR) test results

Exclusion Criteria:

a. Under the age of 18 years old

Primary outcomes:
measure: Oral microbial signature
timeFrame: Day 1
Secondary outcomes:
measure: Nasal microbial signature
timeFrame: Day 1
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: University College Hospital (UCH), UCL Eastman Dental Institute
Study officials:
References:
Clinical trial NCT01139411: The Role of Parents in Adolescent Weight Loss
Official title: Parental Involvement as a Strategy to Enhance Adolescent Weight Control
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Adolescent Obesity
Lead sponsor: The Miriam Hospital
Sponsor class: OTHER
Collaborators: name: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
First posted: 2010-06-08
Enrollment: 49
Sex: ALL
Minimum age (years): 13
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to determine whether a novel model of including parents in adolescent weight control results in greater decrease in adolescent z-BMI compared to an intervention with minimal parent involvement.


Eligibility criteria: Inclusion Criteria:

* Between 30 and 90% overweight
* Parent or guardian willing to participate

Exclusion Criteria:

* Major psychiatric disorder

Primary outcomes:
measure: Body Mass Index
timeFrame: Baseline and at completion of 16 week intervention
Secondary outcomes:
measure: Parent Modeling 1: Dietary Choices (WCSS)
timeFrame: Baseline to post-treatment
measure: Parent Modeling 2: Self-monitoring (WCSS)
timeFrame: Baseline to post-treatment
measure: Parent Modeling 3: Physical Activity (WCSS)
timeFrame: Baseline to post-treatment
measure: Parent Modeling 4: Weight and Body Concerns (FERF-Q)
timeFrame: Baseline to post-treatment
measure: Communication 1: Negative Maternal Weight-related Commentary (FERF-Q)
timeFrame: Baseline to post-treatment
measure: Communication 2: Observed Parent-adolescent Communication Quality (DOCS)
timeFrame: Baseline to post-treatment
Other outcomes:
Locations:
city: Providence
country: United States
facility: The Miriam Hospital
state: Rhode Island
Study officials:
References:
Clinical trial NCT05233111: Brief Prolonged Exposure Therapy Versus Clinical Standard to Reduce Posttraumatic Stress Post Spinal Cord Injury
Official title: Prevention of Posttraumatic Stress: A RCT of Modified Brief Prolonged Exposure Therapy (Brief PE) During Inpatient Rehabilitation Post Spinal Cord Injury (SCI)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Spinal Cord Injuries
PTSD
Post-Traumatic Stress Disorder
Keywords: PTSD
SCI
Spinal Cord Injury
Post-Traumatic Stress Disorder
Lead sponsor: Baylor Research Institute
Sponsor class: OTHER
Collaborators: name: National Institute on Disability, Independent Living, and Rehabilitation Research
First posted: 2022-02-10
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will examine the use brief prolonged exposure (Brief PE) therapy compared to standard clinical care to reduce posttraumatic distress among people who have had a spinal cord injury and are receiving rehabilitation in an inpatient setting.

Detailed description: This is a prospective randomized controlled trial examining the efficacy of brief Prolonged Exposure Therapy (Brief PE) delivered in an inpatient rehabilitation setting post-SCI to reduce PTSD symptoms. The overall goal of this project is to test a Brief PE (three 60-minute sessions) to reduce psychological distress after SCI and to mitigate long-term post-SCI distress including PTSD as well as secondary health outcomes (including depression and general anxiety) at 1, 3, and 6 months from baseline. The intervention group (Brief PE) will be compared to standard clinical care with treatment as usual (TAU).

Eligibility criteria: Inclusion Criteria:

* 18 years of age or older
* Admitted to the inpatient rehabilitation hospital diagnosed with a SCI following a traumatic event

Exclusion Criteria:

* Patients in police custody
* Not fluent in the English language
* Severe cognitive impairment
* Patients who are acutely suicidal
* Patients with active psychosis

Primary outcomes:
measure: Change in PSSI-5: PTSD Symptom Scale - Interview for DSM-5
timeFrame: Baseline, 1 month, 3 months ,6 months
Secondary outcomes:
measure: Change in Patient Health Questionnaire-9
timeFrame: Baseline, 1 month, 3 months ,6 months
measure: Change in Generalized Anxiety Disorder-7 Item
timeFrame: Time Frame: Baseline, 1 month, 3 months, 6 months
Other outcomes:
Locations:
city: Dallas
country: United States
facility: Baylor Institute for Rehabilitation
state: Texas
Study officials:
affiliation: Baylor Scott and White Research Institute-Trauma
name: Mark B Powers, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02514811: Replication of the Teen Outreach Program in the Pacific Northwest
Official title: Northwest Coalition for Adolescent Health (NWCAH) Teen Outreach Program Replication Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Teenage Pregnancy
Lead sponsor: Philliber Research & Evaluation
Sponsor class: OTHER
Collaborators: name: Northwest Coalition of Adolescent Health
name: The Office of Adolescent Health, HHS
First posted: 2015-08-04
Enrollment: 8686
Sex: ALL
Minimum age (years): 12
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The Northwest Coalition for Adolescent Health (NWCAH) replicated the Teen Outreach Program (TOP) in five states across the pacific northwest including Idaho, Alaska, Montana, Oregon, and Washington. The purpose of this study is to measure: at the end of the program year, were TOP students less likely than control group students to report ever being pregnant or causing someone to be pregnant?


Eligibility criteria: Inclusion Criteria:

* Has parental consent and student assent
* Attends one of the schools and/or classes chosen for the program

Exclusion Criteria:

* Lack of consent or assent

Primary outcomes:
measure: Pregnancies
timeFrame: 9 months
Secondary outcomes:
measure: Pregnancies at follow up
timeFrame: 21 months
measure: Sexual behavior
timeFrame: 9 months
measure: Contraceptive use
timeFrame: 9 months
Other outcomes:
Locations:
Study officials:
affiliation: Philliber Research Associates
name: Susan Philliber, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00440011: Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Glaucoma
Ocular Hypertension
Lead sponsor: Allergan
Sponsor class: INDUSTRY
First posted: 2007-02-26
Enrollment: 266
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering, will be randomized to receive either bimatoprost 0.03% or travoprost 0.004% in place of latanoprost 0.005%


Eligibility criteria: Inclusion Criteria:

* Glaucoma or ocular hypertension in both eyes
* Currently being treated with latanoprost 0.005% daily and in need of additional IOP-lowering
* Best-corrected visual acuity of 20/100 or better in each eye
* Visual field within 6 months of study entry

Exclusion Criteria:

* Secondary glaucoma
* Active intraocular inflammation or macular edema
* Intraocular surgery or laser surgery within the past 3 months

Primary outcomes:
measure: Intraocular Pressure (IOP)
timeFrame: Month 3
Secondary outcomes:
measure: Tolerability - Conjunctival Hyperemia
timeFrame: Month 3
Other outcomes:
Locations:
city: San Diego
country: United States
state: California
Study officials:
affiliation: Allergan
name: Medical Affairs
role: STUDY_DIRECTOR
References:
citation: Kammer JA, Katzman B, Ackerman SL, Hollander DA. Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomised, masked-evaluator, multicentre study. Br J Ophthalmol. 2010 Jan;94(1):74-9. doi: 10.1136/bjo.2009.158071. Epub 2009 Sep 1.
Clinical trial NCT03658811: Intense Pulse Light Treatment With Meibomian Gland Expression of the Upper Eyelids in Dry Eye Disease
Official title: Evaluation of the Safety and Efficacy of Intense Pulse Light Treatment With Meibomian Gland Expression of Upper Eyelids for Dry Eye Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dry Eye
Keywords: meibomian gland dysfunction
Lead sponsor: Toyos Clinic
Sponsor class: OTHER
First posted: 2018-09-05
Enrollment: 19
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Patient were enrolled in the study if they had visible signs of upper lid meibomian gland dysfunction and persistent dry eye symptoms and pain despite treatment with conservative dry eye therapies.
Primary purpose: TREATMENT

Brief summary: Upper eyelid treatment has not been used with previously described methods of treatment of dry eye disease using intense pulsed light therapy because the upper lids disease was typically not as advanced as lower lid and because direct treatment of the upper lid was not felt to be necessary as each light pulse extended over the entire periorbita even when concentrated on the lower lid.

Detailed description: Dry eye disease is an under-diagnosed and growing problem. Intense pulsed light has been a proven method of improving the signs and symptoms of meibomian gland dysfunction including lid margin vascularity, meibum viscosity, OSDI mean score and tear break up. This study looks at the safety and effect of treatment of upper lids only to evaluate the safety and efficacy of direct upper lid treatment on the signs and symptoms of dry eye.

Eligibility criteria: Inclusion Criteria:

* subjects older than 18
* cloudy or inspissated meibomian glands in both upper lids
* ocular pain due to dry eye unrelieved by current or prior use of conservative topical dry eye medications including but not limited to over the counter artificial tears, lifitegrast, cyclosporine, or sodium chloride.

Exclusion Criteria:

* Patients with eyelid abnormalities
* intense pulsed light treatment within the past year.
* Patients on oral retinoids,
* patients undergoing intraocular surgery within the past year,
* patients with uncontrolled ocular disease,
* Fitzpatrick skin type V or VI,
* neuro-paralysis in the planned treatment area in the past 6 months,
* pre-cancerous lesions in the planned treatment area.
* New topical eye treatments,
* previous expression of meibomian glands,
* legally blind in one eye.

Primary outcomes:
measure: Non-invasive Tear Break up Time (TBUT)
timeFrame: 2 weeks
Secondary outcomes:
measure: Measure of Visual Analog Scale Pain Over Last 24 Hours
timeFrame: 24 hours
measure: Ocular Discomfort Frequency Assessment on Visual Analog Scale
timeFrame: 24 hours
measure: Measure of Visual Analog Scale Pain
timeFrame: 2 weeks
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Toyos Clinic
state: Tennessee
Study officials:
References:
Clinical trial NCT00503711: Phase I Chinese PK
Official title: An Open Label, Phase I, Rising Multiple Dose, Single Centre Study to Determine the PK and Tolerability of ZD6474 at Different Dose Levels in Chinese Patients With Solid Malignancy Tumor
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Advanced Solid, Malignant Tumors
Keywords: ZD6474 PK
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2007-07-19
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: An open, phase 1 to assess the PK of rising doses of ZD6474 when administered daily in Chinese patients with advanced solid malignant tumors.


Eligibility criteria: Inclusion Criteria:

* histological and/or cytological confirmation of a malignant solid tumor
* refractory to standard therapies or for which no appropriate therapies exist
* WHO performance status 0-2

Exclusion Criteria:

* patients with brain tumors or symptomatic cerebral metastases
* systemic anticancer therapy within the last 4 weeks

Primary outcomes:
measure: Area under the curve (AUC) (0-24) (ng.h/mL) after single dose
timeFrame: Blood sample is collected at 1, 2, 4, 6, 8, 10 & 24 hour after first single dose on day 1
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Research Site
Study officials:
affiliation: Sanofi
name: Clinical Sciences & Operations
role: STUDY_DIRECTOR
References:
citation: Zhang L, Li S, Zhang Y, Zhan J, Zou BY, Smith R, Martin PD, Jiang Y, Liao H, Guan Z. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study. Clin Ther. 2011 Mar;33(3):315-27. doi: 10.1016/j.clinthera.2011.04.005.
Clinical trial NCT05971511: Current Practice for Management of Pneumothorax in Egypt
Official title: Current Practice for Management of Pneumothorax in Egypt
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Pneumothorax
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2023-08-02
Enrollment: 200
Sex: ALL
Minimum age (years): 1
Maximum age (years): 90
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthcare givers dealing with pneumothorax patients

Brief summary: There are standard well-known guidelines for pneumothorax management with minimal difference between societies and associations. We are investigating how much of these guidelines are actually being followed in different healthcare facilites in Egypt. This is a questionnaire that will be sent to all healthcare givers in Egypt acorss different cities and facilities with multiple choice questions presenting different case scenarios and the management options being given to the patient.


Eligibility criteria: Inclusion Criteria:

* being health care giver concerned with management of pneumothorax

Exclusion Criteria:

* being not concerned with management of pneumothorax

Primary outcomes:
measure: Management of pneumothorax
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Faculty Of Medicine
Study officials:
References:
Clinical trial NCT00567411: Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty
Official title: Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Glaucoma
Ocular Hypertension
Keywords: Glaucoma
Laser
laser trabeculoplasty
selective laser trabeculoplasty
intraocular pressure
Lead sponsor: Walter Reed Army Medical Center
Sponsor class: FED
First posted: 2007-12-05
Enrollment: 43
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to compare the safety and efficacy of two drops used to lower eye pressure when given prior to a glaucoma laser procedure.

Detailed description: This is a prospective randomized double blind trial of patients undergoing selective laser trabeculoplasty for primary open angle glaucoma and ocular hypertension. Enrolled patients are randomized to receive one drop of brimonidine 0.1% in one eye and one drop of apraclonidine 0.5% in the fellow eye. The trabecular meshwork in both eyes of each enrolled patient is treated 360 degrees at the same sitting. Intraocular pressure is measured in each eye one hour before applying the study medications and at one hour and one week after laser surgery.

Eligibility criteria: Inclusion Criteria:

* male or female, at least 18 years of age
* Open Angle Glaucoma with inadequate intraocular pressure (IOP) control or evidence of progression (based on optic nerve head appearance and/or visual field changes) despite current medical therapy
* Ocular Hypertension requiring lowering of IOP
* ability to understand and provide informed consent to participate in this study and willingness to follow study instructions and likely to complete all required visits

Exclusion Criteria:

* inability to understand and provide informed consent to participate in this study
* inability/unwillingness to follow study instructions and complete all required visits
* Documented allergy to either brimonidine or iopidine
* Angle Closure Glaucoma
* Congenital/Juvenile Glaucoma
* Neovascular Glaucoma
* Active uveitis

Primary outcomes:
measure: Postoperative IOP
timeFrame: 1 hour and 1 week post surgery
Secondary outcomes:
measure: Overall IOP reduction post SLT
timeFrame: 1 month
Other outcomes:
Locations:
city: Washington
country: United States
facility: Walter Reed Army Medical Center
state: District of Columbia
Study officials:
affiliation: Walter Reed AMC
name: Vladimir S Yakopson, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01312311: Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer
Official title: Phase II Trial of Cisplatin Plus Weekly Docetaxel as the First-line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Nasopharyngeal Cancer
Keywords: nasopharyngeal cancer
weekly docetaxel
cisplatin
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2011-03-10
Enrollment: 51
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The investigators will evaluate weekly docetaxel plus 3-weekly cisplatin regimen as the first-line therapy for recurrent of metastatic nasophayngeal cancer


Eligibility criteria: Inclusion Criteria:

* histologically confirmed nasopharyngeal cancer
* chemotherapy or radiotherapy naive (but, including patients completed 6 months before the enrollment)
* ECOG 0-1
* at least one measurable lesion

Exclusion Criteria:

* other cancer
* pregnat
* docetaxel hypersentitivity history
* severe heart or pulmonary disease

Primary outcomes:
measure: objective response rate
timeFrame: 6 months after the enrollment of the last patients
Secondary outcomes:
measure: number of patients with adverse events
timeFrame: simultaneously when the analysis of primary endpoint
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
Study officials:
References: